Annovis Bio (ANVS) said Wednesday it enrolled the first two participants in its phase 3 trial of buntanetap for early Alzheimer's disease.
The trial will evaluate the safety and efficacy of a daily dose of buntanetap, with treatment lasting for 18 months.
The study includes a 6-month assessment of symptomatic effects followed by a 12-month evaluation of potential disease-modifying effects. Annovis said it plans to enroll more than 750 patients across about 100 sites in the US.
The US Food and Drug Administration approved the Phase 3 protocol for the trial in January, the company added.
Shares of Annovis were down 1.4% in recent trading.
Price: 3.10, Change: -0.04, Percent Change: -1.43
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。